329 results in Exploration of Targeted Anti-tumor Therapy
Most Cited
Sort by :
- Latest
- Most Viewed
- Most Downloaded
- Most Cited
Open Access
Review
Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup ... Matthias G. J. Baud
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
Open Access
Review
The impact of tumour pH on cancer progression: strategies for clinical intervention
Carol Ward ... Simon P Langdon
Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
Open Access
Review
Novel approaches for the rational design of PROTAC linkers
Almaz Zagidullin ... Emil Bulatov
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
Open Access
Review
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
Vincenza Caputo ... Stefania Napolitano
Published: February 28, 2023 Explor Target Antitumor Ther 2023;4:102–138
This article belongs to the special issue The Implementation of Liquid Biopsy in Clinical Practice for Different Solid Tumor
Open Access
Review
The clinical advances of proteolysis targeting chimeras in oncology
Hao Xie ... Jason B. Fleming
Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:511–521
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
Open Access
Review
Potential role of resveratrol and its nano-formulation as anti-cancer agent
Akshay Kumar ... Dilpreet Singh
Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:643–658
This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents
Open Access
Review
Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy
Max Kam-Kwan Chan ... Patrick Ming-Kuen Tang
Published: April 28, 2023 Explor Target Antitumor Ther. 2023;4:316–343
This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
Open Access
Review
New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
Kira-Lee Koster ... Markus Joerger
Published: February 24, 2022 Explor Target Antitumor Ther. 2022;3:27–36
This article belongs to the special issue Antibody-Drug Conjugates
Open Access
Review
PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
Peiyi Zhang ... Guangrong Zheng
Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:259–272
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
Open Access
Review
Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
Rachael Arthur ... Graham Packham
Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
Open Access
Review
Liquid biopsy and glioblastoma
Robert H. Eibl, Markus Schneemann
Published: February 25, 2023 Explor Target Antitumor Ther. 2023;4:28–41
This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
Open Access
Review
Role of estrogen receptor coregulators in endocrine resistant breast cancer
Kristin A. Altwegg, Ratna K. Vadlamudi
Published: August 30, 2021 Explor Target Antitumor Ther. 2021;2:385–400
This article belongs to the special issue Endocrine Resistant Breast Cancer
Open Access
Review
Antibody-drug conjugates: beyond current approvals and potential future strategies
Siddharth Menon ... Hui K. Gan
Published: April 28, 2022 Explor Target Antitumor Ther. 2022;3:252–277
This article belongs to the special issue Antibody-Drug Conjugates
Open Access
Review
An overview of the anti-cancer actions of Tanshinones, derived from Salvia miltiorrhiza (Danshen)
Irum Naz ... Kwang Seok Ahn
Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:153–170
This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
Open Access
Review
Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
Sosmitha Girisa ... Ajaikumar B. Kunnumakkara
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:313–342
This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
Open Access
Review
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
Marilia Barreca ... Francesco Bertoni
Published: December 26, 2022 Explor Target Antitumor Ther. 2022;3:763–794
This article belongs to the special issue Antibody-Drug Conjugates
Open Access
Review
Artificial intelligence in breast cancer imaging: risk stratification, lesion detection and classification, treatment planning and prognosis—a narrative review
Maurizio Cè ... Michaela Cellina
Published: December 27, 2022 Explor Target Antitumor Ther. 2022;3:795–816
This article belongs to the special issue Artificial Intelligence for Precision Oncology
Open Access
Review
AGEs and RAGE: metabolic and molecular signatures of the glycation-inflammation axis in malignant or metastatic cancers
Gowri Palanissami, Solomon F.D. Paul
Published: September 28, 2023 Explor Target Antitumor Ther. 2023;4:812–849
This article belongs to the special issue Biomarkers for Personalized and Precise Cancer Diagnosis and Treatment
Open Access
Review
Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
Marianeve Carotenuto ... Nicola Normanno
Published: April 26, 2022 Explor Target Antitumor Ther. 2022;3:200–223
This article belongs to the special issue Precision Medicine for Cholangiocarcinoma
Open Access
Review
Gut microbiota, an emergent target to shape the efficiency of cancer therapy
Soumaya Kouidhi ... Amel Ben Ammar El Gaaied
Published: April 26, 2023 Explor Target Antitumor Ther. 2023;4:240–265
This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
